Vertex Pharmaceuticals Incorporated (VRTX)

Market Cap	103.89B
Revenue (ttm)	11.72B
Net Income (ttm)	3.68B
Shares Out	253.72M
EPS (ttm)	14.22
PE Ratio	28.79
Forward PE	20.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,357,709
Open	415.61
Previous Close	416.25
Day's Range	406.67 - 416.28
52-Week Range	362.50 - 519.88
Beta	0.32
Analysts	Buy
Price Target	489.17 (+19.46%)
Earnings Date	Nov 3, 2025

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 1991
• Employees: 6,100
• Stock Exchange: NASDAQ
• Ticker Symbol: VRTX
• Website: https://www.vrtx.com

Analyst Summary

According to 26 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price target is $489.17, which is an increase of 19.46% from the latest price.

Price Target

$489.17

(19.46% upside)

Analyst Consensus: Buy